Effects of Inclisiran Combined With Statins on the Morphology of Coronary Vulnerable Plaques - Trial NCT06338293
Access comprehensive clinical trial information for NCT06338293 through Pure Global AI's free database. This Phase 4 trial is sponsored by Nanjing First Hospital, Nanjing Medical University and is currently Not yet recruiting. The study focuses on Coronary Artery Disease. Target enrollment is 40 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Nanjing First Hospital, Nanjing Medical University
Timeline & Enrollment
Phase 4
Mar 01, 2024
May 01, 2025
Primary Outcome
The change rate of the thinnest fibrous cap of vulnerable plaque at the target vascular lesion from baseline to one-year follow-up(△ FCT%)
Summary
Effects of inclisiran + statins vs. statins on the morphology and vascular function of
 coronary vulnerable plaques, in order to provide a better treatment and more detailed imaging
 basis for the treatment of coronary vulnerable plaques.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06338293
Non-Device Trial